Duloxetine 120 mg produced more quality-adjusted life-years (QALYs) than amitriptyline in patients with moderate to severe fibromyalgia.
2
The decision analytical model used a Markov cohort state transition approach to estimate costs and QALYs for four fibromyalgia treatments.
3
Duloxetine 120 mg had an incremental cost-effectiveness ratio of $1,536 per QALY compared to amitriptyline, with a net monetary benefit of $40,075.
4
Sensitivity analyses indicated that duloxetine 120 mg had the highest probability of being cost-effective, though uncertainty remained in model parameters.
5
The study emphasizes the importance of considering societal costs in treatment decisions for fibromyalgia, highlighting duloxetine's economic value.
